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Objectives The primary objective of this study was to compare the effect of therapy with bivalirudin alone versus bivalirudin
plus eptifibatide on platelet reactivity measured by turbidometric aggregometry and thrombin-induced platelet-
fibrin clot strength (TIP-FCS) measured by thrombelastography in percutaneous coronary intervention (PCI) pa-
tients. The secondary aim was to study the relation of platelet aggregation and TIP-FCS to the occurrence of
periprocedural infarction.
Background Bivalirudin is commonly administered alone to clopidogrel naïve (CN) patients and to patients on maintenance
clopidogrel therapy (MT) undergoing elective stenting. The effect of adding eptifibatide to bivalirudin on platelet
reactivity (PR) and TIP-FCS, and their relation to periprocedural infarction in these patients are unknown.
Methods Patients (n  200) stratified to clopidogrel treatment status were randomly treated with bivalirudin (n  102) or
bivalirudin plus eptifibatide (n  98). One hundred twenty-eight CN patients were loaded with 600 mg clopi-
dogrel immediately after stenting, and 72 MT patients were not loaded. The PR, TIP-FCS, and myonecrosis mark-
ers were serially determined.
Results In CN and MT patients, bivalirudin plus eptifibatide was associated with markedly lower PR at all times (5- and
20-M adenosine diphosphate–induced, and 15- and 25-M thrombin receptor activator peptide–induced aggre-
gation; p  0.001 for all) and reduced mean TIP-FCS (p  0.05). Patients who had a periprocedural infarction
had higher mean 18-h PR (p  0.0001) and TIP-FCS (p  0.002).
Conclusions For elective stenting, the addition of eptifibatide to bivalirudin lowered PR to multiple agonists and the tensile
strength of the TIP-FCS, 2 measurements strongly associated with periprocedural myonecrosis. Future studies of PR
and TIP-FCS for elective stenting may facilitate personalized antiplatelet therapy and enhance the selection of pa-
tients for glycoprotein IIb/IIIa blockade. (Peri-Procedural Myocardial Infarction, Platelet Reactivity, Thrombin Genera-
tion, and Clot Strength: Differential Effects of Eptifibatide  Bivalirudin Versus Bivalirudin [CLEAR PLATELETS-2];
NCT00370045) (J Am Coll Cardiol 2009;53:648–57) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.10.045I
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008, accepted October 26, 2008.schemic complications during and after percutaneous cor-
nary interventions (PCIs) are strongly influenced by plate-
et function (1). High post-PCI platelet reactivity (PR) to
denosine diphosphate (ADP) has been correlated with
linical events including periprocedural myocardial infarc-
ion and stent thrombosis (2–4). In a pharmacodynamic
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February 24, 2009:648–57 Bivalirudin With and Without Eptifibatidetudy, eptifibatide administered with clopidogrel and hepa-
in at the time of elective stenting produced consistent and
uperior platelet inhibition that was associated with lower
eriprocedural myonecrosis and inflammation marker re-
ease than was a strategy of clopidogrel and heparin alone
5,6). In addition to high PR to ADP, elevated maximum
ensile strength of a thrombin-induced platelet-fibrin clot
TIP-FCS) measured by thrombelastography has also been
trongly correlated with the occurrence of a 6-month
ost-PCI ischemic event (7).
Platelet function measurements were not performed in
linical trials that reported a noninferior anti-ischemic effect of
ivalirudin therapy alone compared with heparin plus a glyco-
rotein (GP) IIb/IIIa inhibitor in patients treated with PCI
8,9). There are few studies reporting conflicting results re-
arding the potential antiplatelet effects of bivalirudin (10–13).
n a recent study of PCI patients pretreated with a 600-mg
lopidogrel load, administration of bivalirudin produced sig-
ificant immediate additional suppression of ADP-induced
latelet aggregation compared with that of unfractionated
eparin (UFH) (12). In another study, therapy with bivalirudin
r UFH in addition to eptifibatide and clopidogrel resulted in
he same degree of platelet inhibition. Moreover, no significant
ifferences occurred in the platelet inhibition between the
ivalirudin and UFH alone groups (13). Thus, the effect of
ivalirudin with and without a GP IIb/IIIa inhibitor on
latelet function in PCI patients is unclear. Moreover, the
ffect of the latter regimens on TIP-FCS and the relation of
IP-FCS to periprocedural myonecrosis are completely
nknown.
Therefore, the primary objective of the CLEAR PLATE-
ETS-2 (Clopidogrel With Eptifibatide to Arrest the
eactivity of Platelets) study was to compare the effect of
herapy with bivalirudin alone versus bivalirudin plus epti-
batide on platelet reactivity measured by turbidometric
ggregometry and TIP-FCS measured by thrombelastogra-
hy in PCI patients. The secondary aim was to study the
elation of platelet aggregation and TIP-FCS to the occur-
ence of periprocedural infarction. Patients on long-term
lopidogrel maintenance treatment (MT) and clopidogrel
aïve (CN) patients loaded with high-dose clopidogrel
mmediately after stenting were studied, as both clinical
cenarios are commonly encountered in daily practice in
he U.S.
ethods
atients. Two hundred consecutive stable patients undergo-
ng PCI were enrolled in a 2-center, randomized, open-label
tudy between March 2006 and December 2007. The study
as approved by each of the local institutional review boards
nd was registered under http://www.clinicaltrials.gov
NCT00370045). The exclusion criteria were as follows: age
18 years old, a history of bleeding diathesis, acute myocardial
nfarction within 48 h, elevated cardiac markers (above upper
imits of normal for the respective assay), cerebrovascular event 1ithin 3 months, chronic vessel
cclusion, visible thrombus, illicit
rug or alcohol abuse, prothrom-
in time1.5 times control, plate-
et count 100,000/mm3, hemat-
crit 30%, creatinine 2.0 mg/
l, and anticoagulation therapy or
P IIb/IIIa blocker use before the
rocedure.
Subjects were stratified according
o clopidogrel therapy before PCI
nd randomized by a computer-
enerated assignment to eptifi-
atide plus bivalirudin (n 98) or
ivalirudin alone (n  102), thus
roviding 4 treatment groups: 1)
00-mg clopidogrel plus bivaliru-
in (600 mg C  B); 2) 75-mg
lopidogrel plus bivalirudin (75mg
 B); 3) 600-mg clopidogrel
lus bivalirudin plus eptifibatide
600 mg C  B  E); and 4)
5-mg clopidogrel plus bivalirudin
lus eptifibatide (75 mg C  B 
). Clopidogrel naïve patients
n  128) received treatment
ith 600-mg clopidogrel in the
atheterization laboratory imme-
iately after stenting, whereas
atients currently on 75-mg MI
n  72) did not receive a load.
ll patients on maintenance therapy had received daily
lopidogrel for at least 2 weeks before enrollment. All
atients were treated with at least 81-mg daily aspirin for at
east 7 days before enrollment followed by 325-mg daily
spirin and 75-mg clopidogrel. Eptifibatide was administered
sing the ESPRIT (Enhanced Suppression of the Platelet
Ib/IIIa Receptor With Integrilin Therapy) study protocol
s a double bolus (180 g/kg) followed by an infusion (2
g/kg/min) for 18 h after the procedure (14). Bivalirudin
as administered according to the REPLACE-2 (Random-
zed Evaluation in PCI Linking Angiomax to Reduced
linical Events-2) study protocol as a 0.75-mg/kg bolus
ollowed by a 1.75-mg/kg/h infusion for the duration of the
ntervention (8).
lood sampling. Baseline blood samples were obtained in
he catheterization laboratory through the indwelling fem-
ral vessel sheath and transferred to tubes anticoagulated
ith 75 M D-phenylalanyl-L-prolyl-L-arginine chlorom-
thyl ketone (PPACK) (BIOMOL, Plymouth Meeting,
ennsylvania) for aggregation and flow cytometry studies.
lood samples for myocardial necrosis marker analyses and
or thrombelastography were collected in Vacutainer tubes
Becton Dickinson, Franklin Lakes, New Jersey) containing
Abbreviations
and Acronyms
ADP  adenosine
diphosphate
B  bivalirudin
C  clopidogrel
CK-MB  creatinine kinase-
myocardial band
CN  clopidogrel naïve
E  eptifibatide
GP  glycoprotein
MT  clopidogrel
maintenance
treatment/therapy
PCI  percutaneous
coronary intervention
PPACK  D-phenylalanyl-L-
prolyl-L-arginine
chloromethyl ketone
PR  platelet reactivity
R  time to initial platelet-
fibrin clot formation
TEG  thrombelastography
TIP-FCS  thrombin-
induced platelet-fibrin clot
strength
TRAP  thrombin receptor
activator peptide
UFH  unfractionated
heparin.8-mg/ml dipotassium ethylene diamine tetraacetate and
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les were obtained at 2 h, 6 to 8 h, and 18 h.
latelet aggregation. The PPACK tubes were centrifuged
t 120 g for 5 min to recover platelet-rich plasma and further
entrifuged at 850 g for 10 min to recover platelet-poor
lasma. The platelet-rich and platelet-poor plasma were
tored at room temperature to be used within 2 h. Briefly,
latelets were stimulated with ADP (5 and 20 M),
hrombin receptor activator peptide (TRAP [15 and 25
M]), collagen (2 g/ml), and arachidonic acid (2 mM);
nd aggregation was assessed using a Chronolog Lumi-
ggregometer (Model 490-4D) with the AGGRO/LINK
ontrol software (Chronolog, Havertown, Pennsylvania).
ggregation was expressed as the maximum percent change
n light transmittance from baseline, using platelet-poor
lasma as a reference.
hole blood flow cytometry. The ADP-induced surface
xpression of platelet receptors was determined by whole
lood flow cytometry using the 3-color analysis method
Immunocytometry Systems, Cytometry Source Book, Bec-
on Dickinson) with the following monoclonal antibodies:
ITC-conjugated PAC-1 (recognizes activated GP IIb/IIIa
eceptors), R-phycoerythrin (R-PE)-conjugated CD41a
recognizes total GP IIb/IIIa receptors), and CY-Chrome-
onjugated CD62P (recognizes p-selectin [BD Biosciences,
an Diego, California]), as previously described (6). The
-selectin was expressed as percent positive cells (i.e., the
atio of CD62P [CY-Chrome] vs. CD41a [R-PE] positive
ells), and activated GP IIb/IIIa was expressed as mean
uorescence intensity (6).
hrombelastography (TEG). THROMBIN-INDUCED PLATELET-
IBRIN CLOT STRENGTH AND TIME TO INITIAL PLATELET-FIBRIN
LOT FORMATION. The TEG hemostasis analyzer (Haemo-
cope Corp., Niles, Illinois) provides quantitative and qual-
tative measurements of the physical properties of a clot
7,15). The TEG analyzer is a viscoelastic monitor that
easures platelet-fibrin clot strength. Briefly, 1,000 l of
itrated blood were transferred to a vial containing kaolin
nd mixed by inversion. Then, 340 l of the activated blood
as transferred to a reaction cup to which 20 l of 200-mM
alcium chloride was added. The sample was assayed in the
EG analyzer according to the manufacturer’s instructions
o generate the platelet-fibrin clot. Maximum TIP-FCS was
ecorded and expressed in millimeters. The time to initial
latelet-fibrin clot formation (R), an indicator of rate of
hrombin generation, was expressed in minutes (16).
yonecrosis markers. Troponin I, creatinine kinase-
yocardial band (CK-MB), and myoglobin were determined
sing the Triage Cardiac Panel with a Triage Meter (Biosite
nc., San Diego, California). The method is based on a
uorescence immunoassay. The upper limit of normal value for
roponin I is 1.0 ng/ml; for myoglobin, it is 107 ng/ml; and for
K-MB, it is 4.3 ng/ml. The sensitivity of each assay is 0.05
g/ml for troponin I, 1.0 ng/ml for CK-MB, and 5 ng/ml for
yoglobin (data on file, Biosite Inc. [June, 2008]). glinical follow-up and definitions. Adverse ischemic and
leeding events were determined in-hospital, and at 1 and 6
onths after PCI. A physician blinded to the study results
djudicated all end points by reviewing medical record
ource documents. Ischemic events were defined as death
econdary to any cardiovascular cause, myocardial infarction
the occurrence of ischemic symptoms and a troponin I
alue greater than upper limits of normal and/or CK-MB
3 times the upper limits of normal) (17), definite subacute
30 days) and late (30 days) stent thrombosis (18),
nplanned target vessel revascularization, unplanned non–
arget vessel revascularization, and stroke.
Bleeding was quantified according to the TIMI (Throm-
olysis In Myocardial Infarction) trial criteria. Minor bleed-
ng was defined as clinically overt bleeding accompanied by
fall in hemoglobin of 3.0 to 5.0 g/dl (or, when hemoglobin
as not available, a fall in hematocrit of 9% to 15%). Major
leeding occurred when the hemoglobin decreased by 5
/dl (or, when hemoglobin was not available, a fall in
ematocrit of 15%) (19). Mean platelet reactivity and
ean TIP-FCS were calculated as the average of measure-
ents recorded at 2, 6 to 8, and 18 h after PCI.
ample size and statistical analysis. A previous study using
PACK as the anticoagulant has shown that the addition of
ptifibatide to bivalirudin and clopidogrel therapy produced
80% inhibition of baseline aggregation in response to 5-M
RAP, whereas bivalirudin and clopidogrel therapy produced
55% inhibition of baseline aggregation (13). We estimated
hat the eptifibatide plus bivalirudin would produce 25%
reater inhibition of baseline aggregation as compared with
ivalirudin alone. Using SigmaStat (Systat Software, Inc., San
ose, California) the sample size required to detect 25%
reater inhibition with 95% power and with an alpha  0.05
as 97 patients per group.
Categorical variables were reported as percentages and
ompared using the Fisher exact test. Continuous variables
ere reported as mean  SD and compared using either the
npaired t test or Wilcoxon rank sum test after analyzing the
ormal distribution. Analysis of platelet aggregation and
hrombelastography data at different time points for the treat-
ent groups (600 mg C  B vs. 600 mg C  B  E; 75 mg
 B vs. 75 mg B  E) were performed by 2-way repeated
easures analysis of variance to evaluate the effect of group,
ime, and group-time interactions. If significant, post-hoc
esting between baseline and post-treatment time points and
etween different groups at the same time point was carried out
sing Bonferroni correction for multiple testing. A p value
0.05 was considered significant (Systat Software).
esults
emographics and procedural characteristics. Two hun-
red patients were enrolled and had platelet assays per-
ormed. Clopidogrel naïve patients treated with eptifibatide
ad a higher prevalence of prior coronary artery bypass
rafting, more vessels treated, fewer de novo lesions, smaller
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February 24, 2009:648–57 Bivalirudin With and Without Eptifibatideeference vessel diameter, and less frequent angiotensin-
onverting enzyme inhibitor use as compared with CN
atients not treated with eptifibatide (Table 1). Patients on
aintenance clopidogrel therapy treated with eptifibatide
ere more often male, more often treated with angiotensin-
onverting enzyme inhibitors and less often received cal-
ium blockers, and less frequently were smokers than were
atients on maintenance clopidogrel therapy not treated
ith eptifibatide. There were no significant differences in
ematologic indices and creatinine concentrations between
roups (data not shown).
latelet inhibition. Overall, platelet inhibition was mark-
dly greater at 2, 6 to 8, and 18 h after PCI in patients
reated with bivalirudin and eptifibatide compared with
ivalirudin alone, as demonstrated by 15-M TRAP-
nduced aggregation (3  15% vs. 53  22%, 7  13% vs.
8  17%, and 7  10% vs. 50  22%, respectively; p 
.001 for all comparisons) and 25-M TRAP-induced
ggregation (0  8% vs. 55  22%, 6  13% vs. 59  17%,
nd 5  11% vs. 49  21%, respectively; p  0.001 for all
omparisons). Platelet inhibition was similarly much greater
n patients treated with bivalirudin and eptifibatide as
ssessed by 5- and 20-M ADP-induced and collagen-
nduced aggregation (p  0.001 for comparisons at all
imes; data not shown).
atient Demographics and Procedural Characteristics
Table 1 Patient Demographics and Procedural Characteristics
600 mg C  B
(n  66)
600 mg C
(n 
Age, yrs 64 11 65
Male, n (%) 39 (59) 41
Body mass index, kg/m2 32 6 31
Risk factors/medical history, n (%)
Smoking 30 (45) 35
Family history of coronary artery disease 22 (33) 24
Hypertension 55 (83) 51
Hyperlipidemia 48 (73) 50
Diabetes mellitus 26 (39) 21
Prior myocardial infarction 17 (26) 20
Prior coronary artery bypass graft 11 (17) 21
Prior PTCA 22 (33) 21
Baseline medications, n (%)
Beta-blockers 35 (53) 36
Angiotensin-converting enzyme inhibitors 32 (48) 19
Calcium-channel blockers 12 (18) 10
Lipid-lowering agents 51 (77) 43
Procedural characteristics
Ejection fraction (%) 54 8 52
Number of vessels treated 1.2 0.5 1.8
De novo lesion (%) 95 8
Drug-eluting stents, n (%) 46 (70) 47
Bare-metal stents, n (%) 15 (23) 13
PTCA only (%) 5 (7) 2
Reference vessel diameter, mm 3.1 0.5 2.9
Total lesion length, mm 24 19 26 bivalirudin; C  clopidogrel; E  eptifibatide; PTCA  percutaneous transluminal coronary angiograplatelet reactivity in CN patients. Figures 1A to 1E show
latelet aggregation in the CN group. There was signifi-
antly lower overall platelet aggregation in patients treated
ith eptifibatide versus patients not treated with eptifibatide
p  0.001), a decrease in platelet aggregation over time
p  0.001), and a different time course of platelet aggre-
ation between the 2 groups (interaction, p  0.001).
ost-hoc analysis indicated that eptifibatide therapy resulted
n markedly lower platelet aggregation assessed by all
gonists that was immediate and persistent at all times (p 
.001 for all agonists). In patients treated with bivalirudin
lone, the maximum effect of clopidogrel on platelet reac-
ivity was observed at 6 to 8 h (p  0.01 vs. baseline for all
gonists); the effect on TRAP-induced aggregation was
odest compared with aggregation stimulated by the other
gonists. At 2 h, there was no effect of the clopidogrel
oad on collagen or TRAP-induced aggregation com-
ared with baseline in patients treated with bivalirudin
lone.
latelet reactivity in patients on maintenance clopidogrel
herapy. Figures 2A to 2E show platelet aggregation in
atients on maintenance clopidogrel therapy. There was a
ignificantly lower overall platelet aggregation in patients
reated with eptifibatide versus patients not treated with
ptifibatide (p  0.001), a decrease in platelet aggregation
 E
p Value
75 mg C  B
(n  36)
75 mg C  B  E
(n  36) p Value
0.76 64 11 60 14 0.18
0.21 15 (42) 27 (75) 0.003
0.34 31 7 34 10 0.14
0.11 18 (50) 9 (25) 0.02
0.24 14 (40) 14 (39) 0.50
0.44 27 (76) 24 (68) 0.23
0.14 28 (78) 28 (77) 0.50
0.27 16 (43) 17 (48) 0.34
0.23 16 (43) 15 (42) 0.50
0.01 12 (32) 7 (19) 0.11
0.45 21 (59) 19 (54) 0.34
0.29 24 (67) 27 (75) 0.23
0.03 18 (50) 28 (78) 0.008
0.38 13 (36) 6 (17) 0.04
0.19 27 (76) 29 (81) 0.27
0.13 48 10 50 14 0.49
0.001 1.2 0.5 1.3 0.4 0.35
0.03 80 86 0.25
0.19 28 (78) 23 (64) 0.10
0.34 8 (22) 12 (33) 0.15
0.15 0 (0) 1 (3) 0.15
0.01 2.8 0.3 2.8 0.8 1.00
0.48 24 15 24 12 1.00 B
62)
16
(66)
6
(56)
(39)
(82)
(81)
(34)
(32)
(34)
(34)
(58)
(31)
(16)
(70)
7
0.4
5
(76)
(21)
(3)
0.4
12hy.
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Figure 1 Platelet Reactivity in Response to
ADP, TRAP, and Collagen in CN Patients
Platelet reactivity in response to adenosine diphosphate (ADP) (5 and 20 M)
(A and B), thrombin receptor activator peptide (TRAP) (15 and 25 M) (C and
D), and collagen (2 g/l) (E) at baseline and at 2, 6 to 8, and 18 h after per-
cutaneous coronary intervention in clopidogrel naïve (CN) patients. Group “600
mg C  B” (orange lines) received 600-mg clopidogrel and bivalirudin, and
group “600 mg C  B  E” (green lines) received 600-mg clopidogrel, bivaliru-
din, and eptifibatide. *p  0.001, p  0.01 versus baseline; #p  0.001
between groups at the same time point (Bonferroni correction).A
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Figure 2 Platelet Reactivity in Response to
ADP, TRAP, and Collagen in MT Patients
Platelet reactivity in response to ADP (5 and 20 M) (A and B), TRAP (15 and
25 M) (C and D), and collagen (2 g/L) (E) at baseline and at 2, 6 to 8, and
18 h after percutaneous coronary intervention in patients treated with mainte-
nance clopidogrel therapy (MT). Group “75 mg C  B” (orange lines) received
75-mg clopidogrel and bivalirudin, and group “75 mg C  B  E” (green lines)
received 75-mg clopidogrel, bivalirudin, and eptifibatide. *p  0.001 versus
baseline; #p  0.001 between groups at the same time point (Bonferroni cor-
rection). Abbreviations as in Figure 1.
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ggregation between the 2 groups (interaction, p  0.001,
xcept for collagen-induced aggregation). Post-hoc analysis
ndicated that eptifibatide therapy resulted in an immediate
nd significantly marked reduction in platelet aggregation
timulated by all agonists that persisted for the duration of
he infusion (at all times, p  0.001 vs. baseline and
etween groups, except for collagen-induced aggregation).
low cytometry. P-SELECTIN ANDGP IIB/IIIA EXPRESSION. Base-
ine stimulated p-selectin and GP IIb/IIIa expression were
ower in clopidogrel pre-treated patients than in CN patients
p  0.001 for both measurements) (Figs. 3A and 3B). In CN
atients and patients on maintenance therapy, p-selectin
nd GP IIb/IIIa expression were lower at 18 h than at
aseline (p  0.001). At 18 h, GP IIb/IIIa and p-selectin
xpression did not differ among the 4 groups.
IP-FCS. In both CN patients and patients on mainte-
ance clopidogrel therapy there was significantly lower
verall TIP-FCS in patients treated with eptifibatide versus
atients not treated with eptifibatide (p  0.001), and a
ignificant change in TIP-FCS over time (p 0.001) (Figs.
A and 4B).
ime to initial thrombin-induced platelet-fibrin clot
ormation. There was a significant change in R over time,
ith a maximum effect observed at 2 h in patients treated
ith eptifibatide and patients not treated with eptifibatide
n both the CN group and the MT group (p  0.001).
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and GP IIb/IIIa Receptor Expression
(A) Adenosine diphosphate (ADP)-stimulated p-selectin and (B) active glyco-
protein (GP) IIb/IIIa expression at baseline (orange bars) and 18 h after percu-
taneous coronary intervention (green bars).Figs. 4C and 4D).ean 18-h post-PCI platelet aggregation and TIP-
CS. Patients treated with eptifibatide had lower mean 18-h
ost-PCI platelet aggregation in response to all agonists (p 
.001) and lower mean TIP-FCS (p  0.03) than patients
reated with bivalirudin alone (Table 2). Among patients
reated with bivalirudin therapy alone, mean 18-h post-PCI
latelet aggregation was higher in the CN group (p 0.02 for
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a
b
A
t
e
t
P
a
M
m
(
i
E
v
n
n
i
o
i
R
a
t
m
F
t
C
g
C
(
b
m
i
t
1
b
e
a
e
r
s
D
T
e
b
1
A
A oronar
a
C
C
b
654 Gurbel et al. JACC Vol. 53, No. 8, 2009
Bivalirudin With and Without Eptifibatide February 24, 2009:648–57ll agonists) and there was no difference in mean TIP-FCS
etween clopidogrel therapy groups.
Mean 18-h post-PCI platelet aggregation (5 and 20 M
DP, 15 and 25 M TRAP) was lowest in CN patients
reated with eptifibatide (p 0.02). In patients treated with
ptifibatide, mean 18-h post-PCI TIP-FCS was lower in
he CN group compared with MT patients (p  0.09).
eriprocedural myocardial necrosis marker release. The
ddition of eptifibatide to bivalirudin in CN patients and
T patients was associated with lower peak myonecrosis
arker release (p  0.05 for all markers in CN patients)
Table 3). Patients treated with eptifibatide had a lower
ncidence of periprocedural myocardial infarction (Fig. 5).
jection fraction; procedure duration; total stent length;
essel diameter; number of vessels treated; frequency of de
ovo, calcified, and bifurcation lesions; and stent types did
ot differ between patients with and without periprocedural
nfarction (data not shown). There was a higher prevalence
f circumflex intervention in patients with periprocedural
nfarction (56% vs. 23%, p  0.006).
elation of myonecrosis to mean post-PCI aggregation
nd TIP-FCS. Figures 6A and 6B demonstrate that pa-
ients with periprocedural myocardial infarction had higher
ean 5-M ADP-induced platelet aggregation and TIP-
verage Peak Periprocedural Necrosis Marker Release and Mean P
Table 2 Average Peak Periprocedural Necrosis Marker Release
600 mg
C  B C 
Peak CK-MB, ng/ml 3.2 4.2 1.9
Peak troponin-I, ng/ml 0.4 1.0 0.1
Peak myoglobin, ng/ml 135 119 71
18-h mean post-PCI platelet aggregation, %
5-M ADP-induced aggregation 47 18 3
20-M ADP-induced aggregation 53 18 4
15-M TRAP-induced aggregation 67 12 14
25-M TRAP-induced aggregation 76 10 23
2-g/ml collagen-induced aggregation 28 22 2
18-h mean post-PCI TIP-FCS, mm 67 6 63
DP adenosine diphosphate; CK-MB creatinine kinase-myocardial band; PCI percutaneous c
ctivator peptide; other abbreviations as in Table 1.
linical Outcomes
Table 3 Clinical Outcomes
0–3
C  B (n  102)
Ischemic events, n (%)
Death 0 (0)
Stent thrombosis 1 (1)
Myocardial infarction 12 (12)
Unplanned target vessel revascularization 1 (1)
Unplanned nontarget vessel revascularization 2 (2)
Bleeding events, n (%)
Major bleeding 0 (0)
Minor bleeding 1 (1) B  patients treated with clopidogrel plus bivalirudin alone in both clopidogrel naïve patients and pa
ivalirudin plus eptifibatide in both clopidogrel naïve and patients treated with maintenance dose groupsCS than patients without necrosis marker release. Among
he 11 patients with periprocedural infarction diagnosed by
K-MB, 9 had mean 5-M ADP-induced platelet aggre-
ation 40%, and 10 of 11 had TIP-FCS 67 mm.
linical outcomes. There was 1 sudden cardiovascular death
Table 3). One definite stent thrombosis occurred in the
ivalirudin-alone group within 30 days that resulted in a
yocardial infarction and unplanned target vessel revascular-
zation. Thirteen infarctions were periprocedural. Both pa-
ients having unplanned target vessel revascularization at 31 to
80 days also had an initial periprocedural infarction. All major
leeding events within the first 30 days occurred in the
ptifibatide-treated group; 2 were vascular access site related
nd 1 was secondary to a gastric ulcer. The 1 major bleeding
vent occurring beyond 30 days was an intracranial hemor-
hage. All minor bleeding within the first 30 days was access
ite related.
iscussion
he CLEAR PLATELETS-2 study demonstrated that for
lective coronary stenting, the addition of eptifibatide to
ivalirudin therapy in both CN patients and MT patients:
) produced an immediate and marked reduction in peripro-
et Aggregation and TIP-FCS
Mean Platelet Aggregation and TIP-FCS
75 mg
p Value C  B C  B  E p Value
0.05 4.2 6.1 2.4 3.5 0.13
0.05 0.7 1.6 0.3 1.2 0.23
0.001 100 86 88 55 0.48
0.001 33 13 5 9 0.001
0.001 40 15 6 12 0.001
0.001 60 11 21 17 0.001
0.001 71 10 28 19 0.001
0.001 15 13 2 6 0.001
0.003 68 6 65 5 0.03
y intervention; TIP-FCS thrombin-induced platelet-fibrin clot strength; TRAP thrombin receptor
s 31–180 Days
C  B  E (n  98) C  B (n  93) C  B  E (n  93)
0 (0) 1 (1) 0 (0)
0 (0) 0 (0) 0 (0)
2 (2) 1 (1) 0 (0)
0 (0) 2 (2) 0 (0)
1 (1) 1 (1) 1 (1)
3 (3) 1 (1) 0 (0)
3 (3) 1 (1) 0 (0)latel
and
B  E
2.6
0.2
30
4
6
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14
5
60 Daytients treated with maintenance dose groups; C  B  E  patients treated with clopidogrel plus
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February 24, 2009:648–57 Bivalirudin With and Without Eptifibatideedural platelet aggregation stimulated by multiple agonists;
nd 2) reduced overall maximum TIP-FCS measured ex
ivo by TEG. The CLEAR PLATELETS-2 study is the
rst to examine the pharmacodynamic effect of bivalirudin
ith and without eptifibatide in patients on clopidogrel
aintenance therapy. The CLEAR PLATELETS-2 study
s also the first demonstration of a link between high levels
f platelet aggregation and platelet-fibrin clot strength in
ivalirudin-treated patients, and high peak necrosis marker
elease and the occurrence of periprocedural infarctions.
atients who had periprocedural infarction had 25%
reater TIP-FCS compared with patients who had normal
ardiac markers.
Thus, the CLEAR PLATELETS-2 study further
upports the observations of the CLEAR PLATELETS
tudy linking periprocedural myonecrosis to high platelet
ggregation where heparin was used as the anticoagulant
5). Interestingly, mean platelet reactivity in CLEAR
LATELETS-2 was unexpectedly lowest after in-
aboratory loading in CN patients treated with eptifibatide.
n contrast, in patients treated with bivalirudin therapy
lone, mean platelet reactivity was lower in MT patients
han in CN patients. These data suggest that eptifibatide
herapy with in-laboratory loading is associated with a
ynergistic antiplatelet effect. Moreover, the synergistic
ntiplatelet effect was further suggested by lower mean
IP-FCS occurring in CN patients treated with eptifi-
atide. Finally, these physiological observations translated
nto a low incidence of periprocedural infarction and a
omparatively low average peak level of necrosis marker
elease. Our results are consistent with the demonstration by
ev et al. (11) of a more pronounced reduction in ex vivo
latelet-thrombus formation in PCI patients who were
dministered eptifibatide plus UFH compared with biva-
irudin alone.
Our data again support the concept that selected patients
ave a poor antiplatelet response to clopidogrel that is associ-
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Figure 5 Periprocedural Myocardial Infarctions
Incidence of periprocedural myocardial infarction measured by creatinine
kinase-myocardial band (CK-MB), troponin-I, and myoglobin. Orange bars 
75-mg C  B; yellow bars  600-mg C  B; light green bars  75-mg C  B
 E; dark green bars  600-mg C  B  E. ULN  upper limit of normal;
other abbreviations as in Figure 4.ted with an increased risk for periprocedural myocardialnfarction. This observation holds true for CN patients and for
hose on chronic clopidogrel therapy who receive anticoagula-
ion therapy alone in the catheterization laboratory. Because
ide response variability has been observed in patients treated
ith a 600-mg clopidogrel loading dose, with 10% exhibit-
ng nonresponsiveness determined 24 h after loading, the
ddition of a GP IIb/IIIa inhibitor may decrease the occur-
ence of periprocedural infarction in these otherwise unrecog-
ized high-risk patients undergoing elective PCI (20). Among
atients who experienced periprocedural myocardial infarction
easured by CK-MB in the CLEAR PLATELETS-2 study,
5% had mean post-treatment 5-M ADP-induced aggrega-
ion 40%, and 100% had mean TIP-FCS 63 mm. These
easurements may serve as cutpoints for GP IIb/IIIa admin-
stration in future PCI studies. Accordingly, the results of both
he CLEAR PLATELETS and the CLEAR PLATELETS-2
tudies may facilitate future investigations in patients under-
oing elective stenting that are designed to optimize the use
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latelet physiology.
The marked platelet inhibition after eptifibatide treat-
ent in the present study is consistent with the observations
f Saucedo et al. (13), the only prior pharmacodynamic
nvestigation of bivalirudin therapy with and without epti-
batide in elective stenting. The Saucedo study differs from
he CLEAR PLATELETS-2 study in the use of a 300-mg
lopidogrel loading dose administered 15 to 30 min before
CI. In a recent study of patients treated with a 600-mg
lopidogrel loading dose at least 2 h before PCI, bivalirudin
herapy was associated with 4% reduction in 5-M
DP-induced platelet aggregation immediately after the
rocedure (12). In the CLEAR PLATELETS-2 study, we
bserved a significant decrease (mean absolute change of 6%
o 8%) in 5- and 20-M ADP-induced platelet aggregation
t 2 h after PCI in CN patients treated with bivalirudin
lone and a clopidogrel loading dose. However, in clopi-
ogrel pre-treated patients in the CLEAR PLATELETS-2
rial, bivalirudin therapy alone was not associated with
educed platelet aggregation between 2 and 18 h after
dministration, suggesting that the effect observed by Sib-
ing et al. (12) was transient.
In a small study, Schneider et al. (21) reported decreased
latelet reactivity measured by flow cytometry immediately
fter PCI in patients treated with bivalirudin and a 600-mg
lopidogrel load administered immediately after PCI. In the
LEAR PLATELETS-2 study, p-selectin expression fell
t 24 h in all groups. The observation of decreased
-selectin in clopidogrel pre-treated patients in the CLEAR
LATELETS-2 trial is consistent with the observations of
chneider et al (21). Although the mechanism for this
bservation is unclear, these findings suggest that bivaliru-
in administered at the time of PCI modifies the activation
f the platelet by ADP as measured by p-selectin expression.
tudy limitations. Although the current study is the larg-
st pharmacodynamic investigation of the comparative an-
iplatelet effects of bivalirudin with and without eptifibatide
n patients treated with clopidogrel, and is the only study to
valuate the effects on TIP-FCS, the study was not intended
o assess clinical outcomes including bleeding. Therefore,
efinitive statements regarding the relation of treatment to
ong-term patient outcomes will require larger investiga-
ions. In addition, the effect of GP IIb/IIIa therapy on
leeding may counterbalance the benefits of reduced
eriprocedural infarction (22). Previous large-scale studies
emonstrated noninferiority in the occurrence of long-term
schemic end points in patients treated with bivalirudin
lone compared with patients treated with GP IIb/IIIa
nhibitor plus UFH (8,9).
The translational research in the present study focused on
eriprocedural myonecrosis and its relation to platelet func-
ion and platelet-fibrin clot strength. Our study was not
owered to assess the relation of long-term clinical out-
omes to treatment strategies.Currently, it is common practice to treat patients with
nticoagulant therapy alone and to administer a loading
ose of clopidogrel at the time of, or immediately after,
tenting even in high-risk scenarios. In the ACUITY
Acute Catheterization and Urgent Intervention Triage
trategy) trial, in patients not pretreated with a thienopy-
idine loading dose, therapy with heparin plus a GP IIb/IIIa
locker was associated with a trend toward fewer 30-day
schemic events (p  0.08) than was treatment with
ivalirudin alone, whereas patients pre-treated with clopi-
ogrel had the same composite ischemic event rate irrespec-
ive of GP IIb/IIIa blocker use (9). The CLEAR
LATELETS-2 study supports the role of GP IIb/IIIa
lockade in reducing periprocedural infarction in CN pa-
ients and in patients receiving a maintenance dose of
lopidogrel for at least 2 weeks before PCI who did not get
re-stent loading. However, it remains unknown from the
ata of the CLEAR PLATELETS-2 study whether the
trategies of in-laboratory clopidogrel loading plus eptifi-
atide plus bivalirudin and clopidogrel loading 6 to 24 h
efore the procedure plus bivalirudin therapy are associated
ith similar effects on myonecrosis occurrence.
onclusions
n important relation exists between platelet aggregation,
IP-FCS, and the occurrence of post-PCI myonecrosis in
atients treated with bivalirudin. The inhibitory effect of
ptifibatide added to bivalirudin therapy on the physical
haracteristics of the thrombin-induced platelet-fibrin clot
s a new observation. Patients with high thrombin-induced
latelet-fibrin clot strength and platelet aggregation identi-
ed by ex vivo testing are at greatest risk for periprocedural
nfarction. Future studies of PR and TIP-FCS measure-
ents may facilitate personalized antiplatelet therapy with
he appropriate selection of patients for GP IIb/IIIa block-
de in elective stenting.
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enter for Thrombosis Research, Shapiro Building, Suite 209,
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